A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson's Disease.

Trial Profile

A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Dec 2014

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Dec 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 04 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top